CSF2 and cancer: JX-594, or Pexa-Vec, a vaccinia-virus-based vaccine, is modified to express GM-CSF and selectively target cancer cells with high thymidine kinase activity, and it has undergone several trials, including a phase III trial for hepatocellular carcinoma [143,144,145].